Access to biologic medicines for the treatment of rheumatic diseases: Lessons from Australia

International Journal of Rheumatic Diseases

Volumn 11, Issue 1, 2008, Pages 11-14

  Lu, Christine Y ^a   Williams, Ken ^b   Day, Ric ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Health services and health care economics; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB;

ARTICLE; AUSTRALIA; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ECONOMIC EVALUATION; FUNDING; HEALTH CARE ACCESS; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

EID: 54949130661     PISSN: 17561841     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2008.00322.x     Document Type: Article

References (18)

1. Commonwealth Department of Health and Aged Care (2000) The Australian Health Care System, An Outline. Commonwealth Department of Health and Aged Care, Publications Unit, Canberra, ACT.
2. Australian Government Department of Health and Ageing. Pharmaceutical Benefits Scheme - Expenditure and Prescriptions. Available from: http://www.health.gov.au/ (cited 10 Sep 2007): Australian Government Department of Health and Ageing.
3. Australian Institute of Health and Welfare (2005) Health expenditure Australia 2003-04: AIHW Cat. No. HWE 32. Australian Institute of Health and Welfare, Canberra.
4. Australian Government Department of Health and Ageing. Pharmaceutical Benefits Scheme. Available from: http://www.health.gov.au/pbs (cited 10 Sep 2007): Australian Government Department of Health and Ageing.
5. Sansom L (2004) The subsidy of pharmaceuticals in Australia: Processes and challenges. Aust Health Rev 28, 194-205.
6. Henry D (1992) Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals. Pharmacoeconomics 1, 54-67.
7. Lu CY, Williams K, Day R, March L, Sansom L, Bertouch J (2004) Access to high cost drugs in Australia. risk sharing scheme may set a new paradigm. BMJ 329, 415-6.
8. Mason J, Drummond M (1997) Biotechnology: A special case for health technology assessment? Health Policy 41, 73-81.
9. Mason J (1999) Challenges to the economic evaluation of new biotechnological interventions in healthcare. Pharmacoeconomics 16, 119-25.
10. van Rijkom J, Leufkens H, Crommelin D, Rutten F, Broekmans A (1999) Assessment of biotechnology drugs: What are the issues? Health Policy 47, 255-74.
11. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275-85.
12. Australian Government Department of Human Services. Medicare Australia. Available from: http://www.medicareaustralia.gov.au/ (cited 10 Sep 2007): Australian Government Department of Human Services.
13. Lu CY, Williams K, Day R (2007) Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme? Intern Med J 37, 601-6.
14. Lu CY, Williams K, Day R (2007) The funding and use of high-cost medicines in Australia: The example of anti-rheumatic biological medicines. Aus NZ Health Policy 4, 2.
15. Australian Government Productivity Commission (2005) Impacts of Advances in Medical Technology in Australia, Research report. Australian Government Productivity Commission, Melbourne.
16. Lu CY, Ritchie J, Williams K, Day R (2006) Targeted access to high-cost medicines in Australia: Stakeholders'perceptions [abstract]. Intern Med J 36, A81.
17. Lu CY (2007) An examination of systems of access to important high-cost drugs: A critical analysis of the nationally subsidized scheme of access to tumour necrosis factor inhibitors in Australia [PhD]. University of New South Wales.
18. Australian Government Department of Human Services. Highly Specialised Drug Program. Available from: http://www.medicareaustralia.gov.au/ (cited 10 Sep 2007): Australian Government Department of Human Services.